Nalbuphine Sebacate

纳布啡癸二酸

Report date: 2025/03/10 16:59:17
NME

Base Information

Drug NameNalbuphine Sebacate
Drug Alias NameDinalbuphine sebacate癸二酸双纳布啡酯塞纳布啡Sebacoyl Dinalbuphine Ester那布扶林 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor antagonistsKappa opioid receptor agonists
TargetsMu opioid receptorKappa opioid receptor
Therapy Area/IndicationsRotator Cuff InjuriesAcute PainPain +[5] 
Global Approved IndicationsPain
Approved Indications in ChinaN/A
Original Approved Country/TerritoryTaiwan
Original Approved Date2017/03/01
Country/TerritoryCanadaUnited StatesTaiwan +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLumosa Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLumosa Therapeutics Co LtdUbi Pharma Inc. Hsinchu FactoryShanghai Xintan Venture Capital Co Ltd
Inactive CompaniesThe University Of British ColumbiaAssiut University
Active IndicationsAcute PainPainPain, Postoperative
Inactive IndicationsRotator Cuff InjuriesPruritus

Other Information

ATC CodeN02AF02
Related LinksWikipediaDrugBank